<DOC>
	<DOCNO>NCT00121108</DOCNO>
	<brief_summary>This study ( MI-CP117 ) Phase 3 , randomize , double-blind , placebo-controlled trial design determine MEDI-524 compare placebo result clinical efficacy reduction RSV hospitalization otherwise healthy Native American Indian Infants Southwestern United States first RSV season .</brief_summary>
	<brief_title>MEDI-524 ( Motavizumab ) Prevention Respiratory Syncytial Virus ( RSV ) Disease Among Native American Indian Infants Southwestern United States</brief_title>
	<detailed_description />
	<criteria>6 month age young randomization ( child must randomize 6month birthday ) Male female Native American General state good health Written inform consent obtain patient 's parent ( ) legal guardian Gestational age less equal 35 week Chronic lung disease prematurity A bleeding diathesis would preclude IM injection Hospitalization time randomization ( unless discharge anticipate within 10 day ) Active RSV infection ( child signs/symptoms respiratory infection must negative RSV test ) know prior history RSV infection A document wheeze episode enrollment Known renal impairment Known hepatic dysfunction Clinically significant congenital anomaly respiratory tract Chronic seizure evolve unstable neurologic disorder Congenital heart disease ( child uncomplicated CHD [ e.g. , PDA , small septal defect ] child complicate CHD currently anatomically hemodynamically ) Known immunodeficiency Mother HIV infection ( unless child proven infect ) Known allergy Ig product Receipt palivizumab , RSVIGIV , RSVspecific monoclonal antibody , polyclonal antibody ( example , hepatitis B IG , IVIG ) within 3 month prior randomization Anticipated use palivizumab IVIG study ( blood transfusion permit ) Previous receipt RSV vaccine Participation investigational drug product study Any medical social condition , opinion investigator , would adversely affect monitor infant Inability complete study followup period 5 year age</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>